Conference Coverage

Delaying Adalimumab Tx Impairs Long-Term Response

Publish date: July 6, 2012

 

AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Keystone disclosed financial relationships with Abbott, Amgen, AstraZeneca, Biotest, Bristol-Myers Squibb, Centocor, Genentech, Genzyme, Merck, Novartis, Nycomed, Pfizer, Roche, and UCB.

Pages

Recommended Reading

Certolizumab Eased Skin and Joint Symptoms in PsA
MDedge Family Medicine
Rheumatoid Arthritis Etiology Includes Occupational Exposures
MDedge Family Medicine
Three Erosive Joints Made New RA Definition
MDedge Family Medicine
Hydroxychloroquine Cuts Diabetes Risk in Rheumatoid Arthritis
MDedge Family Medicine
Spondyloarthropathy Common a Decade After IBD Diagnosis
MDedge Family Medicine
Switching TNF Inhibitors Pays in Ankylosing Spondylitis
MDedge Family Medicine
Interleukin-17 Inhibitor Scores in Rheumatoid Arthritis Trial
MDedge Family Medicine
Tocilizumab Beats Adalimumab in Monotherapy RA Trial
MDedge Family Medicine
VTE Risk Pumped Up in Rheumatoid Arthritis
MDedge Family Medicine
FDA Panel Considers Metal-on-Metal Hip Replacements
MDedge Family Medicine